⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
DNLI News
Denali Therapeutics Inc. Common Stock
Denali Therapeutics Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
globenewswire.com
DNLI
Denali Therapeutics Announces Proposed Offering of Common Stock and Pre-Funded Warrants
globenewswire.com
DNLI
Royalty Pharma and Denali Therapeutics Announce $275 Million Royalty Funding Agreement
globenewswire.com
RPRX
DNLI
Denali Therapeutics and Royalty Pharma Announce $275 Million Royalty Funding Agreement
globenewswire.com
DNLI
RPRX
Denali Therapeutics Reports Third Quarter 2025 Financial Results and Business Highlights
globenewswire.com
DNLI
Denali Therapeutics Announces Board and Executive Leadership Updates
globenewswire.com
DNLI
Denali Therapeutics Announces FDA Review Extension of BLA for Tividenofusp Alfa for the Treatment of MPS II (Hunter Syndrome)
globenewswire.com
DNLI